

Qingyu Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9175283/publications.pdf>

Version: 2024-02-01

33
papers

1,100
citations

361413

20
h-index

414414

32
g-index

37
all docs

37
docs citations

37
times ranked

1642
citing authors

#	ARTICLE	IF	CITATIONS
1	Multifunctional Graphdiyneâ€¢Cerium Oxide Nanozymes Facilitate MicroRNA Delivery and Attenuate Tumor Hypoxia for Highly Efficient Radiotherapy of Esophageal Cancer. <i>Advanced Materials</i> , 2021, 33, e2100556.	21.0	119
2	Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. <i>Oncogene</i> , 2019, 38, 4990-5006.	5.9	76
3	Involvement of S100A14 Protein in Cell Invasion by Affecting Expression and Function of Matrix Metalloproteinase (MMP)-2 via p53-dependent Transcriptional Regulation. <i>Journal of Biological Chemistry</i> , 2012, 287, 17109-17119.	3.4	64
4	ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2017, 398, 37-45.	7.2	62
5	Regulation of XIAP Turnover Reveals a Role for USP11 in Promotion of Tumorigenesis. <i>EBioMedicine</i> , 2017, 15, 48-61.	6.1	61
6	MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2961-2966.	7.1	58
7	JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. <i>Cell Death and Differentiation</i> , 2020, 27, 55-70.	11.2	53
8	MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 20209-20222.	1.8	49
9	SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4. <i>Cancer Letters</i> , 2020, 469, 390-398.	7.2	44
10	Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. <i>Cell Death and Disease</i> , 2020, 11, 556.	6.3	44
11	Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2016, 7, 64233-64243.	1.8	39
12	OTUD1 Activates Caspaseâ€¢Independent and Caspaseâ€¢Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. <i>Advanced Science</i> , 2021, 8, 2002874.	11.2	37
13	ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. <i>Cancer Letters</i> , 2018, 427, 9-17.	7.2	35
14	TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. <i>Cell Reports</i> , 2020, 30, 98-111.e5.	6.4	35
15	Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner. <i>Journal of Biological Chemistry</i> , 2016, 291, 6831-6842.	3.4	34
16	EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating Snail stability. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 175.	8.6	32
17	ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. <i>Cell Death and Differentiation</i> , 2020, 27, 1981-1997.	11.2	30
18	A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. <i>Molecular Cancer</i> , 2022, 21, 44.	19.2	29

#	ARTICLE	IF	CITATIONS
19	A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy. <i>Cancer Research</i> , 2018, 78, 1069-1082.	0.9	28
20	EIF3H Orchestrates Hippo Pathway-Mediated Oncogenesis via Catalytic Control of YAP Stability. <i>Cancer Research</i> , 2020, 80, 2550-2563.	0.9	24
21	ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression. <i>Cancer Research</i> , 2020, 80, 406-417.	0.9	22
22	Overexpression of S100A14 in human serous ovarian carcinoma. <i>Oncology Letters</i> , 2016, 11, 1113-1119.	1.8	20
23	LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5207-5217.	2.6	18
24	Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8751-8759.	2.0	17
25	New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e12391.	6.9	14
26	Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model. <i>International Journal of Medical Sciences</i> , 2019, 16, 1642-1651.	2.5	13
27	The deubiquitinase USP11 promotes ovarian cancer chemoresistance by stabilizing BIP. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 264.	17.1	13
28	DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 2887-2903.	0.9	12
29	Remodeling of the ARID1A tumor suppressor. <i>Cancer Letters</i> , 2020, 491, 1-10.	7.2	8
30	Silencing of FANCI Promotes DNA Damage and Sensitizes Ovarian Cancer Cells to Carboplatin. <i>Current Cancer Drug Targets</i> , 2022, 22, 591-602.	1.6	4
31	The Prognostic Significance of Anisomycin-Activated Phospho-c-Jun NH2-Terminal Kinase (p-JNK) in Predicting Breast Cancer Patients' Survival Time. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 656693.	3.7	3
32	Purification and Functional Characterization of a Novel Protein Encoded by a Retinoic Acid-Induced Gene, RA28. <i>Annals of the New York Academy of Sciences</i> , 1999, 886, 229-232.	3.8	0
33	Comparison of differential gene expression profiles in human esophageal squamous carcinoma EC8712 cells before and after arsenic trioxide (As ₂ O ₃) treatment. <i>Science Bulletin</i> , 1999, 44, 1581-1587.	1.7	0